We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Regulatory News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

ADS Ex-Dividend Date Scheduled for July, 09 2021

8 Jul 2021 12:19

RNS Number : 6469E
Tiziana Life Sciences PLC
08 July 2021
 

Tiziana Life Sciences plc

ADS Ex-Dividend Date Scheduled for July, 09 2021

THIS ANNOUNCEMENT IS FOR US ADS HOLDERS ONLY

New York, 8 July 2021 - Tiziana Life Sciences plc (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that its American Depository Shares ("ADS"), trading under the ticker TLSA, will begin trading ex-dividend on July 09, 2021.

The non-cash dividend, in the form of an in-specie dividend of one Accustem Sciences Limited ADS (representing 2 ordinary shares in Accustem Sciences Limited) per TLSA ADS, is scheduled to be paid on July 14, 2021.

Shareholders who purchased TLSA prior to the ex-dividend date are eligible for the non-cash dividend. 

Holders of TLSA should also refer to the notice published by JP Morgan, the ADR depositary bank which can be found at https://www.adr.com/drprofile/88875G101 

For further enquiries:

United Kingdom:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

+44 (0)20 7495 2379

United States:

Investors:

Dave Gentry, CEO

RedChip Companies Inc.

1-800-RED-CHIP (733-2447)

or

407-491-4498

dave@redchip.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DIVUPURGMUPGGGR
Date   Source Headline
21st Apr 20204:40 pmRNSSecond Price Monitoring Extn
21st Apr 20204:36 pmRNSPrice Monitoring Extension
21st Apr 20207:00 amRNSNotice of GM
16th Apr 20209:05 amRNSSecond Price Monitoring Extn
16th Apr 20209:00 amRNSPrice Monitoring Extension
15th Apr 20204:31 pmRNSFurther Re: Block Listing Application
15th Apr 202011:05 amRNSSecond Price Monitoring Extn
15th Apr 202011:00 amRNSPrice Monitoring Extension
15th Apr 20207:00 amRNSBlock Listing Application
15th Apr 20207:00 amRNSIssue of Equity
14th Apr 20204:41 pmRNSSecond Price Monitoring Extn
14th Apr 20204:37 pmRNSPrice Monitoring Extension
14th Apr 202011:06 amRNSSecond Price Monitoring Extn
14th Apr 202011:01 amRNSPrice Monitoring Extension
9th Apr 20207:00 amRNSTiziana Develops Treatment For COVID-19 Patients
16th Mar 20205:21 pmRNSClosing of Offer
12th Mar 20207:00 amRNSTiziana U.S. Follow-On Offering of $10 million
11th Mar 20207:00 amRNSTZLS-501 / COVID-19
20th Feb 202010:30 amRNSResult of GM
17th Feb 20207:00 amRNSProposed U.S. Public Offering of ADSs
4th Feb 202012:00 pmRNSDirector/PDMR Shareholding
3rd Feb 20207:00 amRNSNotice of GM
23rd Jan 20207:00 amRNSFiling of SEC Form F-3
21st Jan 20202:45 pmRNSDirector Appointment
14th Jan 202011:00 amRNSDirector/PDMR Shareholding
13th Jan 20207:00 amRNSProposed Cancellation from AIM
9th Jan 20207:00 amRNSFurther re: Foralumab Phase 1 Trial
2nd Jan 20203:00 pmRNSDirector/PDMR Shareholding
4th Dec 20197:00 amRNSForalumab Phase 1 Trial
20th Nov 20197:00 amRNSIssue of Equity and Directorate Change
1st Nov 20197:00 amRNSIssue of CLN
30th Oct 201910:31 amRNSChange to ADS ratio
30th Sep 20197:00 amRNSHalf-year Report
16th Sep 20197:00 amRNSFurther re: Update on IND Application
10th Sep 20197:00 amRNSPhase 1 Clinical Data
4th Sep 20197:00 amRNSPhase 2a Clinical Data
21st Aug 20194:40 pmRNSSecond Price Monitoring Extn
21st Aug 20194:35 pmRNSPrice Monitoring Extension
6th Aug 20197:00 amRNSProposed U.S. Public Offering
22nd Jul 20197:00 amRNSPhase 2a Clinical Data
1st Jul 20197:00 amRNSTeplizumab Article
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:35 pmRNSPrice Monitoring Extension
28th Jun 201910:54 amRNSChange of Adviser
25th Jun 20197:00 amRNSDirector/PDMR Shareholding
24th Jun 20197:00 amRNSArticle on Clinical Activity of OKT3
11th Jun 20197:00 amRNSDirector/PDMR Shareholding
7th Jun 20199:44 amRNSDirector/PDMR Shareholding
3rd Jun 20197:00 amRNSPDMR Dealings
31st May 201911:05 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.